TSHATaysha Gene Therapies, Inc.
The Read
TSHA's stock showed muted reaction to in-line earnings and cash runway confirmations but declined sharply—up to about 26%—when higher operating expenses and wider net losses overshadowed clinical progress updates, then rebounded about 14% on sustained confidence from positive preclinical data despite continued in-line EPS.
The schedule
- Thu1Oct
Stock price reaction to news event, likely tied to regulatory or clinical updates.
- Sun4Oct
End-of-Year Regulatory & Tri
- Thu8Oct
Taysha Gene Therapies stock tumbles on public offering pricing
- Fri16Oct
This data release will test the company's ability to demonstrate clinical efficacy and attract investor interest. The outcome will be a key indicator of the company's progress in its therapeutic pipeline.
- Wed4Nov
Taysha Gene Therapies, Inc. (TSHA)
- Thu24Dec
This event will test the company's ability to present its clinical data and regulatory progress to investors and stakeholders. The outcome will influence the stock's valuation based on the perceived momentum in its pipeline.
- Mon11Jan
This event will test the company's ability to leverage the Breakthrough Therapy designation to attract investment and advance its pipeline. The outcome will also influence the stock's valuation based on regulatory momentum.
- Tue9Feb
This earnings report will test the company's ability to manage cash burn and deliver on clinical progress, especially with the recent FDA Breakthrough Therapy designation. The outcome will be critical for assessing the company's path to commercialization and investor confidence.
- Wed5May
This earnings report will test the company's ability to manage cash burn and deliver on clinical progress, especially with the recent FDA Breakthrough Therapy designation. The outcome will be critical for assessing the company's path to commercialization and investor confidence.
- Wed4Aug
- Wed3Nov
Past
- Wed5Aug
Actual outcome: Bear · $5.69 at outcome
TSHA missed earnings expectations, with an EPS of -0.43 vs. -0.43, but the stock fell 12.1% as cash burn concerns intensified. The news highlighted deepening financial pressure, leading to a bearish reaction. The price dropped below the bear floor, reflecting investor concerns over the company's financial health and path to commercialization.
This earnings report will test the company's ability to manage cash burn and deliver on clinical progress, especially with the recent FDA Breakthrough Therapy designation. The outcome will be critical for assessing the company's path to commercialization and investor confidence.
- Fri5Jun
Actual outcome: Mixed · $5.70 at outcome
Taysha's stock trended higher after it was revealed that the company secured an accelerated FDA pathway for its lead gene therapy, TSHA-102, allowing it to skip Phase 3 trials for Rett syndrome. This shortened development timeline and promising early safety data drove investor optimism, pushing shares steadily upward in the weeks following the regulatory update.
Critical regulatory interaction clarifying manufacturing standards and trial endpoints for TSHA-102.
- Wed6May
Actual outcome: Bull · $6.84 at outcome
Taysha Gene Therapies reported Q1 2026 earnings with an EPS of -$0.12, exactly meeting analyst estimates, alongside a corporate update affirming its clinical pipeline progress. Sustained investor confidence, bolstered by recent positive preclinical data for TSHA-102 in Rett Syndrome, kept the stock trading at elevated levels. Despite a minor 2.3% dip following the release, shares closed at $6.82, successfully exceeding the $6.40 bull target.
First quarter results detailing operating cash flows and affirming pipeline runway.
- Thu19Mar
Actual outcome: Bear · $4.54 at outcome
Taysha Gene Therapies reported in-line EPS of -$0.08 but disclosed higher operating expenses and a wider net loss for the full year. Although the company highlighted clinical progress for its TSHA-102 Rett syndrome program and confirmed it is on track to complete dosing in Q2 2026, concerns over the increased cash burn weighed on investor sentiment, driving the stock below the bear floor.
Taysha reports Q2 2026 financials, with intense market focus on the trajectory of its $40.9M quarterly cash burn against its $276M reserve.
- Thu19Mar
Actual outcome: Mixed · $4.58 at outcome
TSHA reported Q4 2025 EPS of -$0.08, exactly meeting consensus estimates. Although the stock's initial reaction was flat, shares subsequently surged well past the bull target to $6.53 as the in-line earnings and full-year 2026 guidance provided the stability needed for the market to confidently price in the company's long-term pipeline potential.